Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.

@article{Vassiliadis2005PreventionOH,
  title={Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.},
  author={Themistoklis G Vassiliadis and Vassilia Garipidou and Konstantinos Tziomalos and Vassilios Perifanis and Olga I Giouleme and Sofia Vakalopoulou},
  journal={American journal of hematology},
  year={2005},
  volume={80 3},
  pages={
          197-203
        }
}
Administration of immunosuppressive treatment in hepatitis B virus carriers with malignancies is associated with the risk of hepatitis B reactivation. This complication is more frequent in patients with hematologic malignancies because administration of corticosteroids, the mainstay of treatment of these patients, is an independent risk factor for hepatitis B reactivation. When lamivudine is given prior to chemotherapy, it prevents the viral replication during the immunosuppression period… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders

  • Rheumatology International
  • 2008
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2013

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

  • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2012
VIEW 2 EXCERPTS
CITES BACKGROUND